天宇股份(300702.SZ):京聖藥業卡格列淨原料藥通過CDE審評
格隆匯3月21日丨天宇股份(300702.SZ)公佈,公司全資子公司浙江京聖藥業有限公司(簡稱“京聖藥業”)卡格列淨原料藥於近日通過國家藥品監督管理局藥品審評中心(簡稱“CDE”)審評。
卡格列淨主要用於治療2型糖尿病,可與二甲雙胍、二甲雙胍/磺酰脲類藥聯合使用。當單獨使用二甲雙胍血糖控制不佳時,可與二甲雙胍聯合使用,配合飲食和運動改善成人2型糖尿病患者的血糖控制。當聯用二甲雙胍和磺脲類藥物血糖控制不佳時,可與二甲雙胍和磺脲類藥物聯合使用,配合飲食和運動改善成人2型糖尿病患者的血糖控制。本品不建議用於1型糖尿病患者或糖尿病酮症酸中毒(患者)的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.